NIPPV vs.nCPAP During LISA Procedure

NCT ID: NCT05796128

Last Updated: 2023-04-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

202 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-01

Study Completion Date

2023-01-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this randomized controlled study is to compare the efficacy of using NIPPV versus NCPAP during the LISA procedure in very preterm infants.

The main question it aims to answer is:

• Does NIPPV during the LISA procedure decrease the need for a second dose of surfactant or the need of mechanical ventilation during the first 72 hours of life in comparison with NCPAP? Infants with gestational age between 25+0 and 31+6 weeks of gestation with RDS who do not require VM and treated with NCPAP and FiO2 \>0.30 within the first 6 hours of life who received the first dose of caffeine will be eligible for enrollment in the study Participants will be randomized to receive surfactant with conventional LISA procedure, i.e. performed during NCPAP, or with LISA procedure performed during NIPPV.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Distress Syndrome, Newborn

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LISA with NCPAP

In this group, infants will receive NCPAP during LISA procedure.

Group Type ACTIVE_COMPARATOR

Nasal continuous positive airway pressure (NCPAP)

Intervention Type PROCEDURE

In this group, infants will receive NCPAP during LISA procedure.

LISA with NIPPV

In this group, infants will receive NIPPV during LISA procedure.

Group Type EXPERIMENTAL

Nasal Intermittent Positive Pressure Ventilation (NIPPV)

Intervention Type PROCEDURE

In this group, infants will receive NIPPV during LISA procedure.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nasal Intermittent Positive Pressure Ventilation (NIPPV)

In this group, infants will receive NIPPV during LISA procedure.

Intervention Type PROCEDURE

Nasal continuous positive airway pressure (NCPAP)

In this group, infants will receive NCPAP during LISA procedure.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* -Infants with gestational age between 25+0 and 31+6 gestational weeks,
* -RDS which does not require MV
* -Treatment with NCPAP and FiO2 \>0.30 within the first 6 hours of life,
* -First dose of caffeine administered

Exclusion Criteria

* -absence of informed consent,
* -major congenital malformations,
* -hydrops fetalis,
* -chromosomal diseases,
* -previous treatment with surfactant,
* -cardiorespiratory instability requiring treatment with vasoactive drugs,
* -pneumothorax,
* -death within 72 hours of life.
Minimum Eligible Age

0 Hours

Maximum Eligible Age

72 Hours

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Florence

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Carlo Dani

Full Professor of Pediatrics

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Careggi University Hospital, Division of Neonatology

Florence, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIPAL02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.